NASDAQ:GRTX Galera Therapeutics (GRTX) Stock Price, News & Analysis $0.02 0.00 (-6.22%) As of 08/22/2025 03:34 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsInsider TradesOptions ChainSEC FilingsShort InterestTrendsBuy This Stock About Galera Therapeutics Stock (NASDAQ:GRTX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Galera Therapeutics alerts:Sign Up Key Stats Today's Range$0.02▼$0.0250-Day Range$0.02▼$0.0352-Week Range$0.02▼$0.08Volume33,850 shsAverage Volume90,335 shsMarket Capitalization$1.71 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Galera Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for the transformation of radiotherapy in cancer. The company's lead product candidate is avasopasem manganese (GC4419), a small molecule dismutase mimetic for the treatment of radiotherapy induced severe oral mucositis in patients with head and neck cancer (HNC); for the treatment of radiotherapy-induced esophagitis in patients with lung cancer; and for patients with HNC undergoing standard-of-care radiotherapy. It also develops rucosopasem manganese (rucosopasem) to augment the anti-cancer efficacy of stereotactic body radiation therapy in patients with non-small cell lung cancer and locally advanced pancreatic cancer. The company was incorporated in 2012 and is based in Malvern, Pennsylvania. Read More Galera Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks4th Percentile Overall ScoreGRTX MarketRank™: Galera Therapeutics scored higher than 4% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Galera Therapeutics. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Galera Therapeutics is -0.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Galera Therapeutics is -0.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.02% of the float of Galera Therapeutics has been sold short.Short Interest Ratio / Days to CoverGalera Therapeutics has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous month Dividend0.0 / 5Dividend StrengthN/A Dividend YieldGalera Therapeutics does not currently pay a dividend.Dividend GrowthGalera Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted0.02% of the float of Galera Therapeutics has been sold short.Short Interest Ratio / Days to CoverGalera Therapeutics has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous month News and Social Media0.0 / 5News SentimentN/A News Coverage This WeekMarketBeat has tracked 1 news article for Galera Therapeutics this week, compared to 0 articles on an average week. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Galera Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders12.90% of the stock of Galera Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions50.77% of the stock of Galera Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Galera Therapeutics' insider trading history. Receive GRTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Galera Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address GRTX Stock News HeadlinesOTC:GRTX Financials | Galera Therapeutics Inc - Investing.comAugust 24 at 3:26 AM | investing.comGRTX Galera Therapeutics, Inc. - Seeking AlphaJune 24, 2025 | seekingalpha.comA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boom. For retirees, that could mean a way to generate reliable monthly income—without the outdated 4% withdrawal rule, risky trading, or high-fee annuities. If you’re ready to stop worrying about money running out and start enjoying the freedom to cover expenses, treat loved ones, and live life on your terms, this may be exactly what you’ve been waiting for.August 24 at 2:00 AM | Investors Alley (Ad)Galera Therapeutics extends agreement deadlineApril 4, 2025 | investing.comSt. Louis-born Galera Therapeutics sidesteps liquidation, acquires New York biotech companyJanuary 2, 2025 | bizjournals.comGalera Therapeutics completes acquisition of Nova PharmaceuticalsDecember 31, 2024 | globenewswire.comGalera Therapeutics (OTC:GRTX) Stock, Short Interest ReportOctober 6, 2024 | benzinga.comGalera Therapeutics (OTC:GRTX) Stock Quotes, Forecast and News SummaryOctober 6, 2024 | benzinga.comSee More Headlines GRTX Stock Analysis - Frequently Asked Questions How have GRTX shares performed this year? Galera Therapeutics' stock was trading at $0.0458 on January 1st, 2025. Since then, GRTX shares have decreased by 50.7% and is now trading at $0.0226. How were Galera Therapeutics' earnings last quarter? Galera Therapeutics, Inc. (NASDAQ:GRTX) posted its earnings results on Wednesday, November, 10th. The company reported ($0.86) earnings per share for the quarter, missing analysts' consensus estimates of ($0.71) by $0.15. When did Galera Therapeutics IPO? Galera Therapeutics (GRTX) raised $75 million in an initial public offering (IPO) on Thursday, November 7th 2019. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. BofA Merrill Lynch, Citigroup and Credit Suisse served as the underwriters for the IPO and BTIG was co-manager. How do I buy shares of Galera Therapeutics? Shares of GRTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Galera Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Galera Therapeutics investors own include Energy Transfer (ET), Plug Power (PLUG), NGL Energy Partners (NGL), Universal Display (OLED), Nextera Energy Partners (NEP), Verastem (VSTM) and Alerian MLP ETF (AMLP). Company Calendar Last Earnings11/10/2021Today8/24/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:GRTX CIK1563577 Webwww.galeratx.com Phone610-725-1500FaxN/AEmployees30Year FoundedN/AProfitability EPS (Trailing Twelve Months)($0.19) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$59.08 million Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-99.34% Debt Debt-to-Equity RatioN/A Current Ratio9.74 Quick Ratio9.74 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($2.41) per share Price / Book-0.01Miscellaneous Outstanding Shares75,462,000Free Float47,375,000Market Cap$1.71 million OptionableOptionable Beta1.91 5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report This page (NASDAQ:GRTX) was last updated on 8/24/2025 by MarketBeat.com Staff From Our PartnersTrump’s betrayal exposedTrump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredTrump’s “new dollar” could shock Americans"I Made Millions in the Tech Boom. Here's Where I'd Put My Money Today" This man has called some of the big...Stansberry Research | SponsoredHere's the last trade you should make before heading out for the weekend tomorrow.On a quiet Friday afternoon, one trader spotted an overlooked stock. He bought shares. He shut down his ...Timothy Sykes | SponsoredTrump’s SHOCKING Plan to Create MASSIVE Wealth for AmericansJames Altucher says Donald Trump just made a move so surprising, it could go down as the most lucrative presid...Paradigm Press | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Galera Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Galera Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.